Page last updated: 2024-08-24

3-iodobenzylguanidine and caffeine

3-iodobenzylguanidine has been researched along with caffeine in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fujimaki, M; Funayama, M; Hatano, T; Hattori, N; Imamichi, Y; Ishikawa, KI; Kaga, N; Koinuma, T; Li, Y; Miura, Y; Mori, A; Oji, Y; Okuzumi, A; Saiki, S; Taka, H; Ueno, SI; Ueno, T	1

Other Studies

1 other study(ies) available for 3-iodobenzylguanidine and caffeine

Article	Year
Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology, 2018, 01-30, Volume: 90, Issue:5 Topics: 3-Iodobenzylguanidine; Aged; Biomarkers; Caffeine; Case-Control Studies; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2E1; Female; Humans; Male; Mass Spectrometry; Middle Aged; Mutation; Myocardial Perfusion Imaging; Parkinson Disease; Retrospective Studies; Severity of Illness Index	2018

Article

Year

Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease.

Neurology, 2018, 01-30, Volume: 90, Issue:5

Topics: 3-Iodobenzylguanidine; Aged; Biomarkers; Caffeine; Case-Control Studies; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2E1; Female; Humans; Male; Mass Spectrometry; Middle Aged; Mutation; Myocardial Perfusion Imaging; Parkinson Disease; Retrospective Studies; Severity of Illness Index

2018